Clinical trials: Patients With Cancer
Acute Myeloid Leukemia
Mismatched Donor Cells to Treat Acute Myeloid Leukemia
The purpose of this study is to assess the safety and efficacy of infusing immune cells from a donor as treatment for patients with acute myeloid leukemia that is resistant to chemotherapy or who have experienced relapse.
- Trial name
- ATAC-AML-01 (NCT01793025)
- Testing
- ATAC Therapy
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Malignant Solid Tumors
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with…
- Trial name
- NCT06781125
- Testing
- JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
- Volunteers
- 72 people
- Sponsor
- Immorna Biotherapeutics, Inc.
Breast Neoplasms, Triple Negative Breast Neoplasms
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments.
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
- Trial name
- NCT07856225
- Testing
- CDK4/6 Inhibitors, Anti-HER2 Therapy, Standard Breast Cancer Treatment
- Where
- Colombia
- Volunteers
- 370 people
- Sponsor
- Fundación Santa Fe de Bogota
Lymphoma
Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune…
- Trial name
- NCT00317408
- Testing
- anti-thymocyte globulin, busulfan, carboplatin
- Where
- 98 sites in Austria, Belgium and 10 more
- Volunteers
- 96 people
- Sponsor
- European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma
Untreated Early-stage or Locally Advanced Breast Cancer
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
The study is being conducted to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of the combination of SHR-A1811 with Adebrelimab Injection in treatment-naive patients with early-stage or locally…
- Trial name
- NCT06592625
- Testing
- SHR-A1811, Adebrelimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Breast Cancer
Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer
- Trial name
- INV181 (NCT00372476)
- Testing
- Imatinib and Vinorelbine
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery.
- Trial name
- ADOPT-lung (NCT06284317)
- Testing
- Adjuvant durvalumab
- Where
- 42 sites in Australia, Austria and 8 more
- Volunteers
- 290 people
- Sponsor
- ETOP IBCSG Partners Foundation
Fibroid Uterus
Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids
This is a retrospective, case-control study of 75 patients having undergone a robotic-assisted laparoscopic myomectomy were compared to patients having undergone myomectomy via laparotomy.
- Trial name
- NCT00910468
- Testing
- Robot-assisted Laparoscopic myomectomy
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ascher-Walsh, Charles, M.D.
Breast Cancer
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel, epirubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398489
- Testing
- trastuzumab, anastrozole, cyclophosphamide
- Where
- 5 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Technical University of Munich
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Rectal Neoplasms, Rectal Cancer
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative…
- Trial name
- NCT04095468
- Testing
- Preoperative Radio(Chemo)Therapy
- Where
- 7 sites in Poland
- Volunteers
- 215 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Advanced Malignant Solid Tumors
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
This is a multicenter, open-label, phase I clinical study employing a dose-escalation and cohort-expansion design to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in…
- Trial name
- NCT06717750
- Testing
- CSCJC3456 tablet
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Lymphoma
Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00028691
- Testing
- chlorambucil, radiation therapy
- Where
- 11 sites in Belgium, France and 1 more
- Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
Leukemia, Solid Tumours
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
This research is being done because SB939 has been shown to shrink tumours in animals and in some people and seems promising, but we are not sure if it can offer better results than standard treatment.
- Trial name
- NCT01184274
- Testing
- SB939
- Where
- 8 sites in Canada
- Volunteers
- 12 people
- Sponsor
- NCIC Clinical Trials Group
Squamous Cell Carcinoma
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications.
- Trial name
- NCT01232374
- Testing
- Nimotuzumab, cisplatin, Radiotherapy
- Where
- 17 sites in China
- Volunteers
- 144 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Bladder Cancer
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
The goal of this clinical research study is to learn about the tolerability of nivolumab in patients who have bladder cancer, were previously treated with BCG immunotherapy, and who have a cystectomy (removal of all or part of…
- Trial name
- NCT03106610
- Testing
- Nivolumab, Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer Metastatic, Bone Metastases
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included…
- Trial name
- ROTOR (NCT03223597)
- Testing
- Radium-223 dichloride
- Where
- 20 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer
Esophageal Cancer
Cola Ingestion for Esophageal Bolus Impaction
The aim of the study is to observe whether cola ingestion can improve the 24-hour remission rate of acute esophageal impaction in patients with esophageal cancer.
- Trial name
- NCT06652620
- Testing
- Cola
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.